Abcam, ab249526, Anti-TAF9 antibody [EPR12075(B)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal TAF9 antibody. Carrier free. Suitable for ICC/IF, WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR12075(B),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249526 is the carrier-free version of
ab169784
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TAF9 also known as TATA-box binding protein-associated factor 9 is a component of the transcription factor IID (TFIID) complex that plays an essential role in the initiation of gene transcription by RNA polymerase II. This protein has a molecular mass of around 28 kDa and is primarily located in the nucleus of the cell. TAF9 is expressed in various tissues with notable expression levels in liver and kidney.
Biological function summary
TAF9 associates with other proteins to form the TFIID complex an important component in the transcriptional machinery that binds to the TATA box region of the DNA. The interaction of TAF9 with TFIID facilitates the assembly of transcription initiation complexes at gene promoters impacting the transcription of numerous genes. This involvement in transcription regulation highlights TAF9's role in controlling cellular processes that depend on precise gene expression.
Pathways
TAF9 is actively involved in the RNA polymerase II transcription initiation pathway and the signaling pathway related to gene expression. Within these pathways TAF9 interacts with other TAF proteins such as TAF1 and TAF4 ensuring efficient transcription regulation. Its role connects with broader transcriptional networks that manage cellular function and response to environmental cues.
Aberrant function or regulation of TAF9 is linked to liver cirrhosis and transcriptional dysregulation disorders. Changes in TAF9 expression can affect its interactions with components like TAF1 leading to disrupted transcriptional activities and potential disease progression. Understanding TAF9's connections to these diseases may offer insights for therapeutic strategies targeting transcription-related abnormalities.